表 1.
研究人群基本特征
General characteristics of the included studies
| Author | Year | Country | Sample size | Median age (year) | Outcome | Cancer | Follow-up (mon) | Radiation | Median radiation dosage | Immunotherapeutic drugs | Treatment line | NOS | |
| Experiment | Control | ||||||||||||
| NOS: Newcastle Ottawa Scale; U.S: United States; RN/TRIC: radionecrosis/treatment related imaging changes; NSCLC: non-small cell lung cancer; SRS: stereotactic radiosurgery; SBRT: stereotactic radiotherapy; WBRT: whole brain radiotherapy; PD-1: programmed death protein-1; PD-L1: programmed death-ligand 1; OS: overall survival; DBC: distant brain control; CTLA-4: cytotoxic T lymphocyte associated antigen 4; NA: not available; LC: local control; PBI: partial brain irradiation. | |||||||||||||
| Colaco[8] | 2016 | U.S | 180 | - | RN/TRIC | NSCLC, others | 11.7 | SRS | - | PD-1, CTLA-4 | NA | 6 | |
| Chen[9] | 2018 | U.S | 260 | - | OS | NSCLC, others | 9.2 | SRS/SBRT | 20 Gy/1 f | PD-1, CTLA-4 | NA | 8 | |
| Hubbeling[10] | 2018 | U.S | 163 | 61 | 62 | RN/TRIC | NSCLC | 16 | SRS/SBRT; PBI; WBRT | 18 Gy/1 f; 30 Gy/10 f; 35 Gy/12 f | PD-1, PD-L1 | 2 | 9 |
| Martin[11] | 2018 | U.S | 480 | 61 | 62 | RN/TRIC | NSCLC, others | 23.1 | SRS/SBRT; PBI; WBRT | 18-20 Gy/1 f; 25-30 Gy/5 f | PD-1, CTLA-4 | NA | 8 |
| Schapira[12] | 2018 | U.S | 37 | 63 | RN/TRIC | NSCLC | 17.6 | SRS/SBRT; PBI; WBRT | 18 Gy/1 f | PD-1, PD-L1 | NA | 8 | |
| Doi[13] | 2019 | Japan | 100 | 67 | OS | NSCLC | 4.4 | WBRT | 30 Gy/10 f | PD-1 | NA | 7 | |
| Koenig[14] | 2019 | U.S | 97 | 68 | 63 | OS, DBC, RN/TRIC | NSCLC, others | 6.5 | SRS/SBRT; PBI; WBRT | 22 Gy/1 f | PD-1, CTLA-4, PD-L1 | NA | 8 |
| Lanier[15] | 2019 | U.S | 271 | - | DBC | NSCLC, others | 29.9 | SRS | 18 Gy/1 f | PD-1, CTLA-4, PD-L1 | NA | 6 | |
| Li[16] | 2019 | U.S | 125 | 65 | OS | NSCLC, others | > 6 | SRS | - | - | 2 | 7 | |
| Shepard[17] | 2019 | U.S | 51 | - | OS, DBC, RN/TRIC | NSCLC | 7 | SRS | - | PD-1, PD-L1 | 2 | 9 | |
| Enright[18] | 2020 | U.S | 77 | 62 | 63 | OS, LC, DBC | NSCLC | 11.4 | SRS/SBRT | 30 Gy/5 f; 21-24 Gy/1 f | PD-1, PD-L1 | NA | 9 |
| Guénolé[19] | 2020 | France | 194 | 61 | 60 | OS, LC, DBC | NSCLC, others | 11.9 | - | 23.1 Gy/3 f; 33 Gy/3 f | PD-1, CTLA-4, PD-L1 | NA | 7 |
| Lee[20] | 2020 | South Korea | 51 | 62 | 59 | OS | NSCLC | 19.1 | SRS | 19 Gy/1 f | PD-1 | NA | 9 |
| Singh [21] | 2020 | U.S | 85 | 61.9 | OS, RN/TRIC | NSCLC | 12 | SRS/SBRT | 18 Gy/1 f | PD-1, CTLA-4, PD-L1 | 2 | 7 | |
| Singh [22] | 2020 | U.S | 136 | - | DBC | NSCLC | 13.7 | SRS | 22 Gy/1 f | PD-1, PD-L1 | NA | 8 | |
| Kowalski[23] | 2020 | U.S | 179 | 59 | 60 | LC, RN/TRIC | NSCLC, others | 9 | PD-1, CTLA-4, PD-L1 | 2 | 7 | ||
| Silvia[24] | 2022 | Italy | 150 | 65 | 66 | OS | NSCLC | 21 | 18 Gy/1 f; 28.9 Gy/3 f | PD-1, PD-L1 | NA | 8 | |